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Abstract
After the launch of the National Malaria Control Programme in 1953, the number of malaria cases
reported in India fell to an all-time low of 0·1 million in 1965. However, the initial success could
not be maintained and a resurgence of malaria began in the late 1960s. Resistance of Plasmodium
falciparum to chloroquine was first reported in 1973 and increases in antimalarial resistance, along
with rapid urbanisation and labour migration, complicated the challenge that India’s large
geographical area and population size already pose for malaria control. Although several
institutions have done drug-resistance monitoring in India, a complete analysis of countrywide
data across institutions does not exist. We did a systematic review of P falciparum malaria drug-
efficacy studies in India to summarise drug-resistance data and describe changes over the past 30
years to inform future policy. Continued use of chloroquine for treatment of P falciparum malaria
in India will likely be ineffective. Resistance to sulfa–pyrimethamine should be closely monitored
to protect the effectiveness of treatment with artesunate plus sulfadoxine–pyrimethamine, which is
the new first-line treatment for P falciparum malaria. Strategies to reduce the emergence and
spread of future drug resistance need to be proactive and supported by intensive monitoring.
Introduction
India has the largest population in the world at risk of malaria, with 85% living in malarious
zones.1 The combination of Plasmodium falciparum and Plasmodium vivax, six primary
malaria vectors, several ecotypes including urban malaria, and various transmission
intensities ranging from unstable to hyperendemic create a challenging epidemiological
scenario in India. At the time of Indian independence in 1947, there were about 75 million
cases and 800 000 deaths a year.2 After independence, health care was prioritised, and the
control of malaria was one of India’s key aims. In 1953, the National Malaria Control
Programme was launched and protected a population of about 165 million with
dichlorodiphenyltrichloroethane (DDT) spraying.3,4 The control programme developed into
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the National Malaria Eradication Programme in 1958. Reliable surveillance gradually
developed during the eradication period, and the programme seemed to be highly eff ective
with only 99 667 malaria cases and no deaths reported in 1965.4
However, the long-term success of malaria control could not be sustained. Increasing
insecticide resistance in mosquitoes, urbanisation, development projects, population
migration, integration with the general health services, financial difficulties, and other
operational challenges laid the foundation for a resurgence of malaria. In 1976, malaria
cases reached a posteradication peak of 6·47 million cases.5 A new strategy, the modified
plan of operation,5 was introduced in 1977 after which there has been a steady decline in
malaria cases in the country with only 1·4 million reported cases in 2007. However, the
decline in malaria was not equal in both P vivax and P falciparum. The proportion of P
falciparum cases increased to 49% of the total burden in 2007, from 13% in 1978, even
though the annual incidence of P falciparum infection decreased from 0·90 to 0·67 cases per
1000 people during the same interval (figure 1). The change in species dynamics is a cause
for concern because P falciparum is associated with high mortality. Increasing drug
resistance in P falciparum is a possible cause for the changing scenario in India.6
Sehgal and colleagues7 first documented chloroquine-resistant P falciparum in the northeast
Karbi-Anglong district of Assam in 1973. Routine monitoring of antimalarial resistance
using in-vivo-efficacy trials was initiated in 1978 by 13 regional teams. Although several
protocols for drug-resistance monitoring have been used in the past three decades, the test
system generally includes patients with defined criteria, supervised treatment, and follow-up
for clinical and parasitological outcomes. Initial reports of sulfa–pyrimethamine resistance
emerged in 1979, again in Karbi-Anglong, Assam.8 A national antimalarial-drug policy was
introduced in 1982 to improve malaria case management and established sulfa–
pyrimethamine as the treatment for chloroquine-resistant areas. Drug effectiveness
monitoring by the national programme and others has provided data to guide treatment
strategy and update policy. Artesunate plus sulfadoxine–pyrimethamine replaced the latter
alone as the second-line drug in 2005 for use in chloroquine treatment failures, and as the
first-line antimalarial treatment in areas with documented drug resistance. In 2007,
artesunate plus sulfadoxine–pyrimethamine was selected as the first-line treatment in high-
risk districts and areas with identified resistance, with the goal of covering most of the
nation’s P falciparum burden. In 2010 this treatment became the first-line treatment
throughout India.9
Few efficacy trials exist for other antimalarial compounds in India and none for routine
monitoring. Resistance to mefloquine and quinine is reported but seems to be rare10 and
cases are not well documented. Trials of artemisinin combination treatments in India have
consistently shown treatment success above 95%.11,12 Only a few case reports—from
Mumbai, Uttar Pradesh, and Bihar—of chloroquine-resistant P vivax malaria exist.13
Contrary to these reports, systematic trials from across the country have reported 100%
efficacy of standard dose chloroquine (25 mg/kg over 3 days).14 Chloroquine-resistant P
vivax is not a serious concern in India.
The Indian public health system responds to antimalarial failures with evidence-based
policy; however, variations in resistance within the country and a diverse malaria situation
complicate decision making. Furthermore, drug resistance studies have been done by various
institutions, but a complete analysis of Indian data across institutions is absent. In this
systematic review, we summarise data on antimalarial drug resistance in India and describe
temporal and spatial trends, with the aims of informing policy makers and identifying gaps
in understanding.
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Search strategy and selection criteria
We focused our search on the drugs chloroquine and sulfa–pyrimethamine and for the
treatment of P falciparum malaria. We reviewed data gathered between 1978 and 2007 (the
year drug policy changed) from published and unpublished sources. First, we searched
PubMed and Medline databases from June 1, 2008, with the following terms: (“India”) AND
(“malaria”, OR “falciparum”, OR “Plasmodium falciparum”) AND (“resistance”, OR
“resistant”, OR “failure”, OR “efficacy”, OR “sensitivity”). There were no language
restrictions to the search. Second, we retrieved unpublished data from the National Vector
Borne Disease Control Programme, National Institute of Malaria Research, and WHO
headquarters and its Southeast Asia Regional Office. We examined abstracts (or titles if the
abstracts were unavailable) to identify published articles that mentioned any type of P
falciparum resistance (in vivo, in vitro, or molecular) to chloroquine or sulfa–
pyrimethamine. Next, we did a detailed manual review and excluded articles or unpublished
studies that did not describe at least 7 days of follow-up for chloroquine and 28 days for
sulfa–pyrimethamine treatment, did not use standard dosing (ie, 25 mg/kg over 3 days for
chloroquine, or 25 mg/kg of sulfalene or sulfadoxine and 1·25 mg/kg of pyrimethamine as a
single dose), had fewer than 30 patients with complete follow-up, included patients with
severe malaria, included recrudescent patients, did not give exact or graphical data for the
number of patients who completed follow-up and number of treatment failures, and could
not geographically disaggregate results to at least the district level.
Data extraction
NKS and NV searched for and recorded the total number of studies. NKS merged the
datasets and extracted the following information for each study: study year, administrative
divisions (ie, state, district), number of patients, total number of failures, duration of follow-
up, and PCR correction (if any). For studies spanning more than 1 year, the year the study
started was recorded. The smallest unit of geography recorded was the district (second level
administrative unit after the state level, with a population of about 1·0 to 3·5 million). For
the provision of health care, the district is the smallest unit at which at least a public
secondary-care facility is available. Studies spanning many areas of the same district, but in
the same year and by the same investigator were aggregated. Each study was assigned a
geographical region on the basis of state—east (Andaman and Nicobar Islands, Bihar,
Chhattisgarh, Jharkhand, Orissa, and West Bengal), north-central (Haryana, Madhya
Pradesh, and Uttar Pradesh), northeast (Arunachal Pradesh, Assam, Meghalaya, Mizoram,
Nagaland, and Tripura), south (Andhra Pradesh, Karnataka, and Tamil Nadu), and west
(Dadra and Nagar Haveli, Goa, Gujarat, Maharashtra, and Rajasthan).
Drug-resistance monitoring
Since 2005, the cutoff point for routine use of second-line malaria treatment in an area has
been more than 10% total treatment failure with first-line therapy in a minimum sample of
50 patients.15 Before adopting this threshold, routine monitoring of drug effectiveness was
done according to WHO in-vivo protocols. However, most 7-day trials were done according
to the method used by Prasad and colleagues,16 and the cutoff point for treatment change
was 25% or greater RII and RIII resistance in at least 30 patients, which is comparable to
early failures according to new protocols. Currently, WHO-recommended standard test for
therapeutic-drug efficacy provides the information needed for decisions about changes to
treatment policy. Duration of follow-up is determined by the half-life of the drug being
tested but was 28 days for chloroquine and sulfa–pyrimethamine studies done through
routine monitoring. Classification of treatment response varied from study to study, with
most studies using the prevailing WHO criteria at the time. Presently, outcomes are
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classified as early-treatment failures, late-treatment failures, or adequate response according
to the most recent guidelines.15 For our purposes we used a composite definition of
treatment failure, which included the classic RI, RII, and RIII criteria,17 and the revised
WHO criteria,18 which form the basis of current standards. For 28-day follow-up studies this
covers recrudescence after clearance of parasitaemia (RI, late-treatment failure), reduction in
parasitaemia by more than 75% of baseline without clearance (RII, early-treatment failure),
failure to reduce parasitaemia to less than 25% of baseline (RIII, early-treatment failure),
and fever or signs of severe malaria. The follow-up day at which the criteria were assessed
varied between the classic RI, RII, and RIII criteria, in which daily blood smears were
collected up to day 7 versus the revised protocol, which does not. We used the outcome
designated at the time of study, since detailed data for individual patients were not available
precluding reclassification.
Analysis
The proportion of treatment failures was calculated per protocol for each study. The total
number of treatment failures (uncorrected by PCR) was divided by the number of patients,
excluding those lost to follow-up. We recorded the proportion of treatment failures by study
state, region, decade, and follow-up period. We examined the change in chloroquine
resistance by plotting the proportion of failures in each 28-day study by the study year.
Since the strategy is to change policy at 10% or greater total treatment failure with first-line
therapy, the comparison of the proportion of 28-day studies exceeding a certain proportion
of failures by year was done by use of this cutoff. We used Fisher’s exact test to analyse the
change in the proportion of studies exceeding the 10% treatment failure cutoff from when
routine monitoring began to the end of the study period. Change in the proportion of sulfa–
pyrimethamine failures was calculated with the χ2 test. To identify differences in proportion
of chloroquine-treatment failure between regions we did a Kruskal-Wallis non-parametric
test for K-independent samples with SPSS version 14.0. Study periods for comparison were
determined by observation of the slope of change in the proportion of treatment failures. To
produce a national map of existing resistance, we identified districts where a study exceeded
10% treatment failure in any length of follow-up. If a high proportion of failures occurred in
a short study, even more failures would be expected in a longer follow-up period. Districts
endemic for P falciparum were identified by examining surveillance data and selecting areas
with annual incidence greater than 1 per 100 000 population. Maps were produced with
Health Mapper software, version 4.2.
Results
We identified 738 articles, of which 649 were not eligible for detailed review (figure 2). Of
the 89 articles manually reviewed, 41 were included in the review. Some articles reported
the results of multiple studies (ie, in-vivo trials done in different districts). We also compiled
334 unpublished studies of which 315 were included in the analysis. In both published and
unpublished sources, not all studies reported the number lost to follow-up. Some studies
included single-dose primaquine (0·75 mg/kg) for gametocytocidal effect, in accordance
with national policy. PCR-corrected results were available for three studies, but were not
used in our analysis; in these studies, the proportion of treatment failures classified as
reinfections was 0–8%, but not all samples were successfully genotyped. As malaria
transmission in most of India is low to moderate, we expect low rates of reinfection. 161
trials were completed since 2000 compared with 121 in the 1990s, 64 in the 1980s, and 18 in
the late 1970s. 134 studies were done in the eastern region, 72 in the northeast, 64 in the
west, 60 in the south, and 34 in the northcentral area. 119 studies had 7-days of follow-up,
four had 14-days, and 240 had 28-days.
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337 studies investigated chloroquine efficacy in 17 189 patients. The number of studies and
proportion of failures varied between regions and in states within a region (table 1). The
median proportion of chloroquine failure was 35·1% (IQR 13·0–58·2) in studies with a 28-
day follow-up. Studies with 7-day follow-up, which largely detected early treatment failures,
were phased out from 2000 and the last 7-day study was done in 2003. The proportion of
failures detected is higher in 28-day follow-up studies than in 7-day follow-up studies done
in the same areas, because late treatment failures are detected in 28-day follow-up studies.
Studies done between 1978 and 2007 show an increasing proportion of failures to
chloroquine over time (slope=0·73, r2=0·07; figure 3). When routine monitoring of drug
resistance began in 1978–79, two of 17 studies exceeded the 10% threshold used in India to
switch an area to the second-line treatment. In 2006–07, the proportion of chloroquine
studies exceeding 10% treatment failure increased to 35 of 40 studies (p<0.0001; figure 4).
Drug-efficacy studies of chloroquine, with at least 30 patients in any follow-up period, have
exceeded 10% treatment failure in 115 districts (figure 5). These districts represent 20 of 28
states and two of five union territories. The remaining states and territories have low
incidence of P falciparum, or have not done any trial of antimalarial drug resistance.
Chloroquine-efficacy studies done in eight districts did not have more than 10% treatment
failure; however, only three had been done since 2000 and parasite sensitivity might have
changed since. From 1978 to 1985, the median proportion of treatment failure between
regions (northeast > east > west > south > north-central) were significantly different
(p=0·001). For data from 1986–2007, the median proportion of treatment failures increased
substantially in all regions, but the difference was not significant (p=0·06).
Between 1978 and 2007, 26 studies of sulfa–pyrimethamine efficacy including 1431 patients
were done. Three studies, all in Assam, used sulfalene, whereas the rest used sulfadoxine
(National Vector Borne Disease Control Programme, unpublished). The median proportion
of sulfa–pyrimethamine failure was 15% (IQR 0·7–33·1) after 28 days of follow-up. 19
(7·7%) of 246 patients failed sulfa–pyrimethamine treatment in 1984–96 compared with 307
(25·9%) of 1185 in 1997–2007 (p<0·0001; table 2). Most studies were done in northeastern
states, and Arunachal Pradesh on the Chinese and Burmese borders had the highest rates of
treatment failure.
Discussion
Efficacy studies of antimalarial drugs done in India since 1978 show that resistance of P
falciparum to chloroquine increased over time and is present across all regions of the
country. Efficacy of sulfa–pyrimethamine for treatment of P falciparum was reduced in
some recent studies, largely in the northeast.
Nationally, treatment failures of chloroquine increased between 1978 and 2007. However,
the programme of drug-resistance monitoring was designed to detect foci of antimalarial
drug resistance where treatment policy can be changed if needed. Longitudinal trends were
only obtained in a few areas. Study sites were purposely sampled because they fulfilled
several criteria: clinical case reports, outbreak prone areas, high P falciparum burden,
development project areas, reported malaria fatalities.4 Thus, each year there was broad
variation in treatment failure because studies were done in diverse settings. Heterogeneity in
location and frequency of studies created challenges in aggregating data and drawing broad
conclusions. Yet, we saw an increase in the proportion of failures over time; this trend
persisted with the inclusion of 7-day follow-up studies, in which we identified a low mean
proportion of failures because of a short follow-up period. The proportion of studies
exceeding a predefined threshold of treatment failures also increased over time. Before
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2005, a 25% treatment-failure threshold determined the need to change the first-line
treatment. A 10% threshold for first-line therapy was adopted in line with WHO
recommendations and it proved a cost-effective cutoff in India.19 In 2006–07, 88% of trials
done exceeded the 10% treatment-failure threshold for switching an entire area to the
second-line drug. This finding suggests further studies of chloroquine resistance, in the few
areas that have not yet adopted treatment with artesunate plus sulfadoxine–pyrimethamine,
will have little use. Finally, the increase in chloroquine-resistant P falciparum has
contributed to the growing proportion of P falciparum related malaria cases.20 The reversal
of this increase could serve as an indicator of the likely effects of broad treatment with
artesunate plus sulfadoxine–pyrimethamine, which is now used in more than 90% of
reported P falciparum cases.
The median proportion of chloroquine resistance initially varied by region. Most treatment
failures arose in the northeast—the original focus of drug resistance—followed by the
eastern and then western regions. Drug resistance in the northeast likely originated from
neighbouring countries (Thailand 1962, Burma 1969, Bangladesh 1970) that reported
chloroquine-treatment failures before India.21–24 Drug-resistant strains of P falciparum
might have then spread across India through host movements, particularly through migrant
labourers travelling from eastern India to the western states.25 Thus, chloroquine resistance
in India is now widely distributed, and our data show a geographical clustering of resistant
areas rather than isolated foci. Few studies have been done in most places that have not
identified chloroquine resistance. Changing treatment policy so that second-line drugs are
given at smaller administrative levels, such as primary-health centres, blocks, or cluster of
blocks, has helped India to limit malaria mortality and morbidity in patients who receive
care at government facilities. However, such a policy shift does not seem to have stemmed
the spread of drug resistance. In the face of continued selection pressure, strains of drug-
resistant malaria will spread. Without geographical barriers, transportation between nearby
areas and interactions between catchment populations assures an exchange of vectors and
parasite strains. Even when drug sensitivity remains, if the area is close to sites with drug
resistance then strains will interact, and with continued chloroquine use, resistant strains will
proliferate due to a competitive advantage. Conversely, effective treatments implemented on
large scales can reduce malaria transmission and might even reduce existing drug resistance
in other settings.26–28 Thus, minimisation of uneven drug pressure through use of an
effective drug throughout a large geographical unit, such as a district or even cluster of
districts, is an effective strategy to prevent the spread of drug resistance. Such a change in
treatment policy will also need fewer drug-efficacy studies and reduce operational
challenges related to drug supply.
As in other control programmes, the dose and choice of sulfa derivative used in India has
changed over time.29 Originally, several sulfa derivatives were used, including sulfalene, but
these were gradually replaced by sulfadoxine. The two-tablet adult dose was as efficacious
as the three-tablet dose in initial trials; however, the three-tablet dose became the standard.29
Studies we surveyed were done with the full dose only. Effectiveness of sulfa–
pyrimethamine was reduced in parts of the country, particularly the northeast region. These
study results might be a conservative estimate because sulfa–pyrimethamine failures can
occur after 28 days, and a 42-day follow-up is now recommended. Since a widespread use of
sulfa–pyrimethamine would increase resistance, artesunate plus sulfadoxine–pyrimethamine
replaced monotherapy because combination treatments, particularly artemisinin-based
treatments, are promoted as a means for both the provision of effective treatment and the
prevention of drug resistance.30 There is concern that as the partner drug, pre-existing
resistance to sulfa–pyri methamine could compromise combination treatment. Additionally,
although age-group blister packs of artesunate plus sulfadoxine–pyrimethamine pills are
being made available, in principle, a coformulated drug would be ideal. Although these
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constraints were recognised at the time of inclusion of artesunate plus sulfadoxine–
pyrimethamine into the national drug policy, this was the only option available because
coformulated artemisin-based combination treatments were not registered. Treatment with
artesunate plus sulfadoxine–pyri methamine has shown adequate safety and efficacy in India
and is available in sufficient quantities. Trials with several fixed-dose combinations, such as
artesunate–mefloquine, artesunate–amodiaquine, artemether–lumefantrine,
dihydroartemisinin–piperaquine, and artesunate–pyronaridine, have been completed to
provide local efficacy data for other options. Determination and preparation of back-up
combination treatments is high priority. In the meantime, effectiveness of treatment with
artesunate plus sulfadoxine–pyrimethamine needs careful monitoring.
Our study has two main limitations. First, a range of quality-control issues varied between
studies or were not reported, including selection criteria, microscopy techniques, drug
quality, and record keeping. Our results are derived from a per-protocol analysis and
differences in the proportion of patients completing follow-up and reasons for loss to follow-
up could affect estimates of treatment failure. Although exact numbers are not available for
most studies, in our experience loss to follow-up rarely exceeded 10%, and in most studies
was zero. This low proportion is because of the mass-fever survey approach used for
recruitment in many studies, by which study teams enrol the entire study population at once
and then remain in the area until the completion of the trial.
Second, the variability in study methods is small compared with differences in the number
of studies and their location each year. Diversity in time scales and sites in which studies
were done make data aggregation difficult. Operational factors influenced the number and
location of studies. Treatment failure is an indirect measure of true parasite resistance,
because host immunity and pharmacokinetics contribute to outcomes. Expected variation in
such factors between different areas could cause some of the variation in treatment failure
rather than any difference in resistance. Caution should be exercised in attempting to
interpret any summary estimate of treatment failure across time and place. Thus, we did not
produce a meta-analysis, but rather we focused on overall trends with systematic review.
The large number of studies analysed should mitigate the limitation posed by the temporal
and spatial variability of the data.
Current initiatives and future steps
The National Vector Borne Disease Control Programme has responded to the challenge of
drug resistance with several strategies.31 Rational drug use is being promoted to reduce
overall drug pressure—eg, phasing out presumptive treatment, strengthening microscopy
services, and extending the availability of rapid diagnostic tests to peripheral areas using the
nationwide community health worker system (Accredited Social Health Activists [ASHA])
under the National Rural Health Mission.32 Inadequate dosing or the use of improper
treatments, such as the use of parenteral artemisinin derivatives for treating uncomplicated
malaria, can promote resistance. New guidelines have been developed and are being updated
in cooperation with the National Institute of Malaria Research,31,33 which present treatment
policy in an accessible format for public and private physicians to improve compliance.
Regulation is in place that bans the sale of oral artemisinin monotherapy. A group of 15
alternating sentinel sites were selected in 2009 to enable the longitudinal monitoring of
antimalarial-drug resistance. Molecular techniques, such as PCR correction of treatment
failures, are now used in trials of antimalarial-drug efficacy, with help from research
institutions such as the National Institute of Malaria Research.
Further research and programmes are needed to combat antimalarial-drug resistance in
India. Previously, chloroquine treatment, with primaquine as a gametocytocidal drug, was
standard. Artemisinin combination treatments show useful gametocytocidal properties but
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do not eliminate mature gametocytes.30 How the addition of single-dose primaquine to
artesunate plus sulfadoxine–pyrimethamine will affect malaria transmission or the spread of
drug-resistant strains in India is unclear. In-vitro susceptibility and molecular markers mirror
intrinsic antimalarial resistance to a drug and their changes precede clinical resistance.34
Molecular and in-vitro monitoring could supplement efficacy trials and provide early
warning of drug resistance.
Finally, introduction of resistant malaria into non-immune populations such as refugees or
migrants increases the opportunity for spread of resistance, because parasites with low or
moderate resistance would be cleared in semi-immune populations.35 In India, antimalarial
resistance for chloroquine and sulfa–pyrimethamine was fi rst reported near the international
border with Burma.36 Reports of tolerance of malaria to artemisinin along the Thai–
Cambodian border, and the historical westward spread of drug-resistant strains, generate
concern about the long-term effectiveness of artemisinin-combination therapies in India.37
Best practices for malaria control along border areas and in migrant populations in India
need to be established. Overall, a robust and specific plan to combat drug-resistant parasites
will be fundamental in fulfilling our commitment to malaria control in India.
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Data from the National Vector Borne Disease Control Programme (unpublished).
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Number of studies of chloroquine resistance with 28-day follow-up in India between 1978
and 2007 and the proportion of treatment failures greater than or equal to 10%
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Districts with 10% or greater chloroquine-treatment failure (red) in any study between 1978
and 2007 and in Plasmodium falciparum endemic areas (pink), and districts without reported
P falciparum transmission (blue)
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Table 2
Results of 28-day studies of sulfa–pyrimethamine efficacy done in India between 1978 and 2007
Year n Total failures (%)
Arunachal Pradesh
  Changlang 1992 57 4 (7%)
  Changlang 1999 43 19 (44%)
  Changlang 2002 65 35 (54%)
  Changlang 2006 67 38 (57%)
  Lohit 2002 70 12 (17%)
  Lohit 2006 212 81 (38%)
Assam
  Darrang 1993 36 0 (0)
  Darrang 2004 37 4 (11%)
  Karbi-Anglong 1984 30 8 (27%)
  Karbi-Anglong 2001 51 18 (35%)
  Nagaon 2002 78 0 (0)
  Nagaon 2003 32 0 (0)
  Nalbari 1992 30 1 (3%)
  North Lakhimpur 2007 47 6 (13%)
  Sonitpur 2001 49 21 (43%)
  Sonitpur 2003 32 0 (0)
Madhya Pradesh
  Mandla 1997 114 42 (37%)
Orissa
  Kandhamal 2004 38 1 (3%)
  Keonjhar 2002 61 0 (0)
  Sundargarh 1991 60 6 (10%)
West Bengal
  Bankura 2005 35 6 (17%)
  Jalpaiguri 1996 33 0 (0)
  Jalpaiguri 2001 58 11 (19%)
  Puruilia 2000 30 7 (23%)
  Puruilia 2003 31 0 (0)
Total 1431 326 (23%)
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